Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report

doi:10.12998/wjcc.v13.i33.113751

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 33

This Article

(41)

(50)

(0)

(12)

(781)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Nov 26, 2025; 13(33): 113751
Published online Nov 26, 2025. doi: 10.12998/wjcc.v13.i33.113751

Full Size Figure Download Figure

Figure 3 Marked clinical improvement at six-week follow-up, with resolution of widespread erythema and palmoplantar scaling after antiviral therapy and reintroduction of ixekizumab.

Citation: Berjawi A, Attieh R, Younes M, Beydoun K, Fassih I, Tannous Z. Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report. World J Clin Cases 2025; 13(33): 113751
URL: https://www.wjgnet.com/2307-8960/full/v13/i33/113751.htm
DOI: https://dx.doi.org/10.12998/wjcc.v13.i33.113751

Berjawi A, Attieh R, Younes M, Beydoun K, Fassih I, Tannous Z. Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report. World J Clin Cases 2025; 13(33): 113751 [PMID: 41356087 DOI: 10.12998/wjcc.v13.i33.113751]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.